Eczema is a common ailment for many people, but a more severe type of eczema not as well-known, atopic dermatitis (AD), may have a new treatment option available.
AD is a more severe manifestation of eczema symptoms, and based on my previous research into the patient and caregiver community, there is a need for more awareness on their diagnosis.
A recent study from the American Association for the Advancement of Science recently released data from a phase 2 clinical trial of etokimab’s efficacy to treat AD. According to AnaptysBio, etokimab ““inhibits the activity of IL-33, a pro-inflammatory cytokine,” which can help modulate skin inflammation.
Please read more about the study here, and more about etokimab here.
Sources:
https://stm.sciencemag.org/content/11/515/eaax2945
https://www.anaptysbio.com/pipeline/etokimab/
